Innovation in action
Piedmont offers one of the largest and broadest R&D portfolios of Rx companion animal products in development for the US and global markets. We specialize in delivering game-changing innovations for the most significant unmet needs in companion animal therapy and developing novel and differentiated products with significant growth potential. Based on independent market research and market tracking data, sales of our portfolio products are projected to reach $500+ million annually.
First in utilizing soft chew technology
Many of Piedmont’s products have featured our innovative chewable drug delivery platform. The palatable, meat-free treat is made without water and without extrusion methods to protect the integrity and potency of active ingredients.
Looking to the future
Our therapeutic areas of focus include some of the most common ailments among pets, including infectious diseases, pain, parasites, atopic dermatitis, and chronic kidney disease.
We plan to out-license our products currently in development, addressing unmet needs for dogs and cats: